{
  "claims": [
    {
      "claim_id": "C01",
      "claim": "Intratumoral mRNA vaccination improves tumor sensitivity to immune checkpoint blockade (anti-PD-L1).",
      "strength": "moderate",
      "evidence": [
        {
          "quote": "The paper investigates whether intratumoral delivery of an mRNA vaccine can create an interferon-rich inflammatory state that improves sensitivity to anti-PD-L1 therapy.",
          "line_ref": "L11"
        },
        {
          "quote": "Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort.",
          "line_ref": "L46"
        }
      ],
      "caveat": "The study supports a biologically coherent hypothesis that intratumoral mRNA vaccination can prime tumors for stronger ICI responses, but prospective randomized studies are required before clinical protocol changes are justified."
    },
    {
      "claim_id": "C02",
      "claim": "mRNA vaccination triggers local innate sensing and induces a type I interferon response within the tumor.",
      "strength": "strong",
      "evidence": [
        {
          "quote": "Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.",
          "line_ref": "L42"
        },
        {
          "quote": "Marked induction after mRNA vaccination in tumors",
          "line_ref": "L31"
        }
      ],
      "caveat": "Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings."
    },
    {
      "claim_id": "C03",
      "claim": "Prior SARS-CoV-2 mRNA vaccination correlates with improved survival outcomes in patients receiving ICI treatment.",
      "strength": "tentative",
      "evidence": [
        {
          "quote": "Vaccinated subgroup had improved survival under ICI treatment",
          "line_ref": "L30"
        },
        {
          "quote": "a retrospective cohort of metastatic patients receiving ICI treatment, compared by prior SARS-CoV-2 mRNA vaccination status.",
          "line_ref": "L15"
        }
      ],
      "caveat": "The human analysis is retrospective and non-randomized; residual confounding is likely."
    },
    {
      "claim_id": "C04",
      "claim": "mRNA vaccination increases the diversity of antigens presented on MHC-I, enhancing tumor visibility.",
      "strength": "strong",
      "evidence": [
        {
          "quote": "A broader peptide repertoire appears on MHC-I, improving tumor visibility to T cells.",
          "line_ref": "L44"
        },
        {
          "quote": "Strong expansion of MHC-I-presented landscape",
          "line_ref": "L29"
        }
      ],
      "caveat": "Mouse model effects may not map one-to-one to all human tumors."
    }
  ]
}
